BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.52 -2.96%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
